1
|
Stewart BW and Wild CP: The global and
regional burden of cancer. (World Cancer Report). WHO; pp. 26–31.
2014
|
2
|
Imai N, Ishigami M, Ishizu Y, Kuzuya T,
Honda T, Hayashi K, Hirooka Y and Goto H: Transarterial
chemoembolization for hepatocellular carcinoma: A review of
techniques. World J Hepatol. 6:844–850. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Cockman ME, Masson N, Mole DR, Jaakkola P,
Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ and Maxwell
PH: Hypoxia inducible factor-alpha binding and ubiquitylation by
the von Hippel-Lindau tumor suppressor protein. J Biol Chem.
275:25733–25741. 2000. View Article : Google Scholar : PubMed/NCBI
|
4
|
Lim CS, Kiriakidis S, Sandison A, Paleolog
EM and Davies AH: Hypoxia-inducible factor pathway and diseases of
the vascular wall. J Vasc Surg. 58:219–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Otrock ZK, Makarem JA and Shamseddine AI:
Vascular endothelial growth factor family of ligands and receptors:
Review. Blood Cells Mol Dis. 38:258–268. 2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Dias S, Hattori K, Heissig B, Zhu Z, Wu Y,
Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, et al:
Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling
pathways is essential to induce long-term remission of
xenotransplanted human leukemias. Proc Natl Acad Sci USA.
98:10857–10862. 2001. View Article : Google Scholar
|
7
|
Villegas G, Lange-Sperandio B and Tufro A:
Autocrine and paracrine functions of vascular endothelial growth
factor (VEGF) in renal tubular epithelial cells. Kidney Int.
67:449–457. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sison K, Eremina V, Baelde H, Min W,
Hirashima M, Fantus IG and Quaggin SE: Glomerular structure and
function require paracrine, not autocrine, VEGF-VEGFR-2 signaling.
J Am Soc Nephrol. 21:1691–1701. 2010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Peng S, Wang Y, Peng H, Chen D, Shen S,
Peng B, Chen M, Lencioni R and Kuang M: Autocrine vascular
endothelial growth factor signaling promotes cell proliferation and
modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Hepatology. 60:1264–1277. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Marchand GS, Noiseux N, Tanguay JF and
Sirois MG: Blockade of in vivo VEGF-mediated angiogenesis by
antisense gene therapy: Role of Flk-1 and Flt-1 receptors. Am J
Physiol Heart Circ Physiol. 282:H194–H204. 2002.
|
11
|
Pavco PA, Bouhana KS, Gallegos AM, Agrawal
A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot
PA, et al: Antitumor and antimetastatic activity of ribozymes
targeting the messenger RNA of vascular endothelial growth factor
receptors. Clin Cancer Res. 6:2094–2103. 2000.PubMed/NCBI
|
12
|
Shen L, Zhou Q, Wang Y, Liao W, Chen Y, Xu
Z, Yang L and Sun LQ: Antiangiogenic and antitumoral effects
mediated by a vascular endothelial growth factor receptor 1
(VEGFR-1)-targeted DNAzyme. Mol Med. 19:377–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ivy SP, Wick JY and Kaufman BM: An
overview of small-molecule inhibitors of VEGFR signaling. Nat Rev
Clin Oncol. 6:569–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Sun LQ, Cairns MJ, Saravolac EG, Baker A
and Gerlach WL: Catalytic nucleic acids: From lab to applications.
Pharmacol Rev. 52:325–347. 2000.PubMed/NCBI
|
15
|
Schubert S, Gül DC, Grunert HP, Zeichhardt
H, Erdmann VA and Kurreck J: RNA cleaving ̔10–23̓ DNAzymes with
enhanced stability and activity. Nucleic Acids Res. 31:5982–5992.
2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Chen X, Xiao E, Shu D, Yang C, Liang B, He
Z and Bian D: Evaluating the therapeutic effect of hepatocellular
carcinoma treated with transcatheter arterial chemoembolization by
magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol.
26:109–113. 2014. View Article : Google Scholar
|
17
|
Prat F, Centarti M, Sibille A, Abou el
Fadil FA, Henry L, Chapelon JY and Cathignol D: Extracorporeal
high-intensity focused ultrasound for VX2 liver tumors in the
rabbit. Hepatology. 21:832–836. 1995.PubMed/NCBI
|
18
|
Okada M, Kudo S, Miyazaki O, Saino T,
Ekimoto H, Iguchi H, Hirano S, Kuboki H, Kadosawa H and Takeuchi T:
Antitumoral efficacy and pharmacokinetic properties of pirarubicin
upon hepatic intra-arterial injection in the rabbit V x 2 tumour
model. Br J Cancer. 71:518–524. 1995. View Article : Google Scholar : PubMed/NCBI
|
19
|
Ramirez LH, Orlowski S, An D, Bindoula G,
Dzodic R, Ardouin P, Bognel C, Belehradek J Jr, Munck JN and Mir
LM: Electrochemotherapy on liver tumours in rabbits. Br J Cancer.
77:2104–2111. 1998. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhang G, Dass CR, Sumithran E, Di Girolamo
N, Sun LQ and Khachigian LM: Effect of deoxyribozymes targeting
c-Jun on solid tumor growth and angiogenesis in rodents. J Natl
Cancer Inst. 96:683–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang L, Lu Z, Ma X, Cao Y and Sun LQ: A
therapeutic approach to nasopharyngeal carcinomas by DNAzymes
targeting EBV LMP-1 gene. Molecules. 15:6127–6139. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhang L, Gasper WJ, Stass SA, Ioffe OB,
Davis MA and Mixson AJ: Angiogenic inhibition mediated by a DNAzyme
that targets vascular endothelial growth factor receptor 2. Cancer
Res. 62:5463–5469. 2002.PubMed/NCBI
|
23
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
24
|
Raskopf E, Vogt A, Sauerbruch T and
Schmitz V: siRNA targeting VEGF inhibits hepatocellular carcinoma
growth and tumor angiogenesis in vivo. J Hepatol. 49:977–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|